Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

Efficacy & Safety ProfileEfficacy & Safety ProfileAcutePivotal TrialLong-Term Safety StudyTriptan Unsuitable StudyPreventivePivotal TrialPivotal Open-Label Safety ExtensionPrior Inadequate Response StudyCHALLENGE-MIG StudyDosingAbout NurtecAbout NurtecMechanism of ActionPatient ProfilesAccess & SupportAccess &
SupportSearch for CoveragePrior AuthorizationPrescribingSavings & SupportResources

For the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults1

Patient ProfilesPatients with migraine you may encounter in your practiceAcute Treatment Patients JennySeeking additional treatment options to help meet her treatment goalsJenny – 36-year-old artist

Migraine History

  • 2–4 monthly migraine days
  • Symptoms: photophobia, phonophobia
  • Triggers: menses, light, stress

Goals

  • A treatment that she can tolerate and that she can take at the first sign of migraine pain
  • Fast relief and return to normal function, with a lasting response

Comorbidities: Depression and anxiety, managed with treatment.

  • Certain antidepressants may have drug interactions with Nurtec ODT.1,2
  • See full Prescribing Information for drug interactions.
  • Certain antidepressants may have drug interactions with Nurtec ODT.1
See full Prescribing Information for drug interactions.

Medications

  • Acute: OTC medications, previously tried 2 different triptans
  • Preventive: none

Why Nurtec ODT

  • Acute pivotal trial: Patients experienced rapid and sustained pain relief and return to normal function, including results as early as 1 hour. Safety was also evaluated.3
  • Studied in patients who are unsuitable for triptan use: In these patients, Nurtec ODT was studied for pain relief at 2 hours postdose, return to normal function, sustained response, and safety.4
  • Long-term safety study: The safety profile of Nurtec ODT was studied across the acute clinical trial program, including in an open-label, 52-week study.2
OTC=over-the-counter.

Read clinical trial results for Nurtec ODT as an acute treatment for migraine.

View the dataLoading PaigeRe-evaluating treatment options due to attacks becoming more disablingPaige – 31-year-old teacher and motherMigraine History
  • 4 monthly migraine days
  • Symptoms: visual aura, photophobia (MBS)
  • Triggers: menses, alcohol, limited sleep

Goals

  • Treatment evaluation due to more disabling and prolonged attacks
  • Minimal redosing or need for rescue medication 
  • Rapid and sustained relief with return to normal function
Medications
  • Acute: sumatriptan, OTC medications; previously tried rizatriptan and almotriptan
  • Preventive: beta-blocker
Why Nurtec ODT
  • Acute pivotal trial: Patients taking Nurtec ODT experienced rapid and sustained pain relief and return to normal function, including results as early as 1 hour. Safety profile was also evaluated.3
    • 86% of patients did not use rescue medication within 24 hours postdose.3
  • Studied in patients who are unsuitable for triptan use: Patients with a treatment history like Paige’s were part of a study evaluating pain relief and return to normal function at 2 hours, as well as safety profile.4
MBS=most bothersome symptom; OTC=over-the-counter.

Learn more about the efficacy of Nurtec ODT in patients with acute migraine who are unsuitable for triptan use.

 See the efficacy Loading MatthewLooking to try an oral gepantMatthew – 25-year-old business professional

Migraine History

  • Prescription-treatment naive
  • 4–5 moderate to severe attacks per month, lasting 24–48 hours
  • Symptoms: photophobia, phonophobia (MBS)
  • Triggers: work stress, frequent airplane travel

Goals

  • Treatment that restores his ability to function normally during an attack
  • Effective acute migraine treatment with rapid relief
  • A prescription migraine treatment that reduces his reliance on NSAIDs

Medications

  • Acute: NSAIDs (ibuprofen)
  • Preventive: none

Why Nurtec ODT

  • Acute pivotal trial: Patients like Matthew experienced rapid and sustained pain relief and return to normal function, including results as early as 1 hour.3
  • Long-term safety study: The safety profile of Nurtec ODT was studied across the acute clinical trial program, including in an open-label, 52-week study.5
  • Nurtec ODT can be taken on the go: No water needed and can be taken with or without food.1*
ReferencesMBS=most bothersome symptom; NSAIDs=nonsteroidal anti-inflammatory drugs.Store Nurtec ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).1

See the long-term safety study results of Nurtec ODT for acute treatment of migraine.

 Read the results LoadingPreventive Treatment Patients CarlyWants to try a preventive treatment to reduce frequency of attack

Migraine History

  • 8–10 monthly migraine days
  • Symptoms: photophobia, phonophobia, irritability
  • Triggers: erratic sleep, stress, dehydration

Goals

  • Reduced frequency of MMDs, especially her moderate to severe days

Medications

  • Acute: previously tried triptans and OTC medications
  • Preventive: none

Why Nurtec ODT

  • Preventive pivotal trial: For patients like Carly, Nurtec ODT provided proven efficacy in reducing MMDs, with almost half of patients achieving a ≥50% reduction in moderate-severe MMDs at weeks 9–12.1
  • Long-term safety study: Safety profile was evaluated in the pivotal trial and in a 52-week long-term study.6
Carly – 24-year-old Master's studentReferencesMMDs=monthly migraine days; OTC=over-the-counter.

Read clinical trial results for Nurtec ODT as a preventive treatment for migraine.

 See the clinical data Loading PatriciaSeeking different treatment options due to increasing MMDsPatricia – 39-year-old customer service manager

Migraine History

  • 8–10 severe monthly migraine days
  • Symptoms: aura, photophobia, phonophobia
  • Triggers: hormonal changes, stress, weather changes, sleep changes

Goals

  • A well-tolerated oral preventive that can help reduce MMDs, especially her moderate-severe migraine days

Medications

  • Acute: Tried a few triptans and OTC medications
  • Preventive: Previously tried magnesium, riboflavin, coenzyme Q10, methylfolate combination, topiramate, and amitriptyline

Why Nurtec ODT

  • Preventive pivotal trial: For patients like Patricia, Nurtec reduced MMDs, with ~50% of patients achieving a ≥50% reduction in moderate-severe MMDs (weeks 9–12).1
  • Prior inadequate response: Evaluated reduction of MMDs among patients taking Nurtec ODT, who had prior inadequate response to oral preventives.7
  • Safety profile: Learn more about the safety profile of Nurtec ODT, which was studied across the preventive clinical trial program.6
MMDs=monthly migraine days; OTC=over-the-counter.

Learn more about the efficacy of Nurtec ODT in patients with a history of inadequate response to oral preventive medication.

 Review the results Loading
Have a treatment option that helps address individual patient needs.
When you need to treat or help prevent episodic migraine,
there's a Nurtec for that.
References:Nurtec ODT. Package insert. Pfizer Inc.Kudrow D, Hutchinson S, Pixton GC, Fullerton T. Safety of rimegepant in adults with migraine and anxiety, depression, or using antidepressants: analysis of a multicenter, long-term, open-label study. Pain Ther. 2025;14(1):237-255.Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745.Ashina M, McAllister P, Ramirez LM, et al. A phase 4 randomized double-blind placebo-controlled study of rimegepant for acute treatment of migraine in adults unsuitable for triptan use. Oral presentation at: American Headache Society 67th Annual Scientific Meeting; June 19-22, 2025; Minneapolis, Minnesota.Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44(4):1-11.Kudrow D, Croop RS, Thiry A, Lipton RB. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache. 2026;66(2):407-416.Pozo-Rosich P, Lopez JAG, Lisewski P, et al. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia. 2025;45(11):1-13. Get Nurtec ODT samples. Explore Loading Learn more about the Acute Clinical Data. See the results Loading Find out about the Preventive Clinical Trials. Read the data Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-NNT-USA-5806
You are now leaving PfizerPro You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-NNT-USA-5221
INDICATIONSNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine
Please click here for full Prescribing Information.
Important Safety Information Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted. Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.If signs or symptoms of Raynaud’s phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%). Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby.

Lactation: The transfer of rimegepant into breast milk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.

IndicationsNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine
Please click here for full Prescribing Information.
Help your patients get started with Nurtec ODT
Ordering samples

For your patients with migraine, providing samples can be a great way to have them get started with their Nurtec ODT treatment. Follow the link below to order.
 


Please be aware that your eligibility to order Nurtec ODT samples on PfizerPro is determined by your
experience prescribing Nurtec ODT within the last 12 months.

Quarterly allocation

If you do not see Nurtec ODT on your sample list, come back later and try again. It may not have you on the list because it doesn’t have your history established or your quarterly allocation may have been exhausted—in both cases, the system will update.
 PP-NNT-USA-5221